Micro-X Ltd (ASX:MX1) Announces $6.0M Capital Raising
Micro-X Ltd (ASX:MX1) secures $6M capital raising and a strategic $2.4M investment to advance its focus on medical imaging.
Micro-X Ltd (ASX:MX1) secures $6M capital raising and a strategic $2.4M investment to advance its focus on medical imaging.
Recce Pharmaceuticals Ltd (ASX:RCE) corrects its Q4 2024 Cash Flow Report, reflecting positive net operating cash inflows.
Arovella Therapeutics (ASX:ALA) requests a trading halt pending a material update related to its recent capital raising placement.
ImpediMed Limited (ASX:IPD) secures US$15M growth capital facility to support the expansion of its digital health platform.
AdAlta Limited (ASX:1AD) accelerates its ‘East to West’ cellular immunotherapy strategy, signing additional term sheets to enhance pipeline growth.
Cynata Therapeutics (ASX:CYP) publishes study comparing Cymerus™ iPSC-derived MSCs to conventional MSCs, highlighting enhanced functionality and consistency.
Little Green Pharma (ASX:LGP) acquires Health House distribution business for $375,000, enhancing its vertical integration and strategic growth.
Audeara Limited (ASX:AUA) secures a US$917,000 purchase order, validating its AUA Technology’s commercial potential in global markets.
Biome Australia Limited (ASX:BIO) secures a co-investment with FaBA to develop its BMB18 probiotic strain, supported by government funding.
Pro Medicus Limited (ASX:PME) secures a A$53M, 7-year contract with BayCare to implement its Visage 7 Enterprise Imaging Platform.